ANDHealth+ does not operate like a traditional grant program. Once selected, all funds are disbursed to participants in tranches, based on achievement of milestones and successful navigation of agreed go/no-go points and participating SMEs are provided with hands-on support from a dedicated and experienced ANDHealth team and international industry leaders.
Each SME is assigned a bespoke Industry Advisory Panel (IAP) of senior executives drawn from ANDHealth’s multi-disciplinary and multi-sectoral expert network. ANDHealth will also work with its community and consumer engagement partners to identify appropriate consumer, community and end user representatives for each company’s IAP.
With the guidance and support of ANDHealth and its IAP, each SME will prepare a project plan designed to accelerate their progress on the commercialisation pathway, increasing their ability to be enterprise-customer ready and de-risking their technology for institutional investors.
Project plans may include pivotal activities for product development, clinical outcomes, manufacturing, commercial strategy, regulation and reimbursement.
Successful companies should expect (and be prepared for):
The program and project funding are delivered across two stages, spanning up to 24 months:
Stage 1 (4-6 months): Activities focus on identifying key risks and addressing them using third-party expertise and the expertise of each company’s Industry Advisory Panel.
Stage 2 (14-18 months): Activities focus on achieving key clinical and commercial milestones which drive institutional investment and/or enterprise customer uptake and ultimately patient impact.
Additional funding opportunities: Follow-on funding from unallocated Stage 1 and 2 funds will be awarded on a competitive basis across intakes. An SME is eligible for up to a maximum value of $5 million in funding awarded for approved across Stage 1, Stage 2 and follow-on funding activities.
For further information on project types and program stages,
click here.
